Entering text into the input field will update the search result below

SLNO Soleno Therapeutics, Inc.
Stock Price & Overview

$28.94-0.89 (-2.98%)4:00 PM 12/04/23
NASDAQ | $USD | Post-Market: $28.12 -0.82 (-2.83%) 7:20 PM

Charts

FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Ratings Summary

SA Analysts
Wall Street
Quant
Now3M ago6M ago
Valuation
-Rating: Not Covered
Growth
-Rating: Not Covered
Profitability
-Rating: Not Covered
Momentum
-Rating: Not Covered
Revisions
-Rating: Not Covered

See SLNO ratings with Premium.

People Also Follow

Company Profile

Soleno Therapeutics, Inc. logo
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Employees
25
Founded
1999
Address
  • 203 Redwood Shores Parkway
  • Suite 500
  • Redwood City, CA, 94065
  • United States
Phone Number
650 213 8444
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.